Saturday, September 25

The judge revokes the ozone treatment of the COVID patient in Barcelona for not having scientific endorsement

Reversal of the Barcelona judge who agreed to apply a pseudo-ozone therapy to a COVID-19 patient last week. The magistrate has considered the arguments put forward by the Generalitat’s Health Department and has revoked the precautionary measure that she had taken, at the request of the family, so that a man in a critical situation could receive treatment that the hospital did not see as adequate.

The order agrees with the medical authorities and states that, “from all the medical documentation in the proceedings and especially the forensic medical report issued at the request of this Court, it is possible to conclude that there is currently no scientific evidence that the treatment in question may bring benefits for the cure “of the patient. For this reason, he corrects his previous decision and cancels the order to apply this therapy. With this order he closes the controversy generated between the patient and the Generalitat. His had been the second judicial decision in a few weeks in favor of this type of ozone treatment, after a similar case in Villarreal, in which a judge first authorized its application to end up annulling it.

Last week Salut issued a statement in which it avoids giving details about the patient, the hospital in which he is admitted or the court that has made the decision, but in which they regretted the situation generated. Ozone “is not authorized as a medicine by the regulatory agencies”, they explain, “and its use is not contemplated in the action protocols of the Catalan Health Service, based on scientific evidence”.

In the same sense, they warned that this therapy “may have side effects such as irritation from inhalation or respiratory distress, cough and phlebitis if the administration is intravenous.” “Also,” the statement continues, “it has been indicated that it is dangerous to administer ozone to pregnant women and in patients with hypothyroidism or glucose-6-phosphate dehydrogenase deficiency.” Salut also recalls that the Spanish Medicines Agency (AEMPS) has already spoken out against this therapy.

Leave a Reply

Your email address will not be published. Required fields are marked *